Table 1.
Characteristics of the study patients.
| Characteristic | All Patients (N = 125) | Patients with 1 year follow-up (N =88) |
|---|---|---|
| Female | 75 (60%) | 54 (61%) |
| Age in years at JIA diagnosis | ||
| Median (IQR) | 7.1 (3.7 – 11.8) | 7.0 (3.4 – 11.8) |
| Months from diagnosis to initiation of TNF-α inhibitor | ||
| Median (IQR) | 6.6 (0.7 – 35.6) | 5.6 (0 – 37.6) |
| Initiated TNF-α inhibitor within6 months of diagnosis | 61 (49%) | 45 (51%) |
| JIA category | ||
| Persistent oligoarthritis | 26 (21%) | 14 (16%) |
| Extended oligoarthritis | 6 (5%) | 4 (5%) |
| RF-polyarthritis | 17 (14%) | 14 (16%) |
| RF+ polyarthritis | 5 (4%) | 3 (3%) |
| Psoriatic | 17 (14%) | 10 (11%) |
| ERA | 53 (42%) | 42 (48%) |
| Undifferentiated | 1 (1%) | 1 (1%) |
| Methotrexate use | ||
| Prior | 60 (48%) | 39 (44%) |
| Concurrent | 114 (91%) | 83 (94%) |
| Oral glucocorticoid use | ||
| Prior chronic | 14 (11%) | 8 (9%) |
| Burst | 50 (40%) | 40 (45%) |
| Baseline clinical characteristics | ||
| Joint count, median (IQR) | 2 (1 – 4) | 2 (1 – 4) |
| 5 or more active joints at baseline | 28 (23%) | 20 (23%) |
| Active enthesitis | 36 (29%) | 28 (32%) |
| ESR, median (IQR) | 11 (6 – 29) | 12 (7 – 32) |
| CHAQ, median (IQR) | 0.5 (0.12 – 1) | 0.5 (0.12 – 1) |
| MD global, median (IQR) | 24 (18 – 35) | 25 (18 – 38) |
| First TNF-α inhibitor | ||
| Etanercept | 104 (83%) | 73 (83%) |
| Infliximab | 7 (6%) | 6 (7%) |
| Adalimumab | 14 (11%) | 9 (10%) |
(IQR, interquartile range; JIA, juvenile idiopathic arthritis; TNF-α, tumor necrosis factor alpha; RF, rheumatoid factor; ERA, enthesitis-related arthritis; ESR, erythrocyte sedimentation rate; CHAQ, Childhood Health Assessment Questionnaire)